Rxbio, Inc. — Department of Health and Human Services SBIR Phase I: NIAID
Rxbio, Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $297,087
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIAID
- Solicitation
- PA12-044
- NAICS
- —
- Place of performance
- TN
- Period
- 2015-03-01 → 2016-05-31
Description
DESCRIPTION provided by applicant The looming threat of nuclear attacks and recent non terrorist related accidents Fukushima nuclear disaster has increased national and global attention to the need for medical countermeasures RxBio has identified a first in class proprietary small molecule Rx which significantly protects the gut and the hematopoietic system from exposure to lethal doses of ionizing radiation We have demonstrated the radiomitigant efficacy of Rx in murine and non human primate NHP models for GI ARS Gastrointestinal Acute Radiation Syndrome RxBio has completed a spectrum of drug development activities in consultation with FDA The overall goal of this proposal is to complete manufacturing chemistry studies to support regulatory activities in advancing Rx lysine for eventual FDA licensure The Phase I program specific aims are to evaluate the raw material standards for acceptance to manufacture highly pure Rx lysine by examining the stability of oleyl alcohol and investigating potential degraded or source impurities of oleyl alcohol via identification and structural characterization and to investigate process improvement studies and stressing of current chemistry process in each manufacturing step and demonstrate the robustness of modified process via lab scale synthesis of highly pure API Proposed studies will be completed in months with two major deliverables a Establishing the acceptance criteria for oleyl alcohol for GMP scale up effort th month b Improved manufacturing process to generate highly pure Rx lysine and batch record for lab scale synthesis effort th month PUBLIC HEALTH RELEVANCE Inevitably nuclear accidents occur and nuclear attacks and radiation terrorism have become a real threat to our nation since September Currently there are no FDA approved medical countermeasures available today for treating radiation injury We are proposing to develop a novel class of radiation medical countermeasures to protect the American people and mankind from radiation injury